Valuation: Celsion Corporation

Market Cap 8.87M 7.66M 7.2M 6.55M 12.32M 849M 12.5M 84.51M 33.12M 425M 33.29M 32.56M 1.42B P/E 2026 *
-0.66x
P/E 2027 * -0.85x
Enterprise Value 8.87M 7.66M 7.2M 6.55M 12.32M 849M 12.5M 84.51M 33.12M 425M 33.29M 32.56M 1.42B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.90%+15.32%+56.99%+92.41% 62.99B
+0.15%-1.74%+2.18%+490.82% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+22.80%+20.26%+0.11%-5.11% 23.3B
+2.64%+5.60%+41.93%-13.79% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+2.24%+7.36%+44.16%+153.11% 13.16B
Average +2.56%+3.23%+59.71%+199.16% 31.17B
Weighted average by Cap. +2.04%+5.48%+59.14%+165.43%

Financials

2026 *2027 *
Net sales - -
Net income -14.82M -12.8M -12.05M -10.95M -20.59M -1.42B -20.89M -141M -55.37M -710M -55.65M -54.44M -2.37B -19.31M -16.68M -15.69M -14.26M -26.83M -1.85B -27.22M -184M -72.14M -925M -72.5M -70.93M -3.08B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-